[go: up one dir, main page]

ZA982253B - Therapeutic compositions. - Google Patents

Therapeutic compositions.

Info

Publication number
ZA982253B
ZA982253B ZA9802253A ZA982253A ZA982253B ZA 982253 B ZA982253 B ZA 982253B ZA 9802253 A ZA9802253 A ZA 9802253A ZA 982253 A ZA982253 A ZA 982253A ZA 982253 B ZA982253 B ZA 982253B
Authority
ZA
South Africa
Prior art keywords
therapeutic compositions
therapeutic
compositions
Prior art date
Application number
ZA9802253A
Other languages
English (en)
Inventor
Richard Lewis Veech
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Publication of ZA982253B publication Critical patent/ZA982253B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Biological Depolymerization Polymers (AREA)
ZA9802253A 1997-03-17 1998-03-17 Therapeutic compositions. ZA982253B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4085897P 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
ZA982253B true ZA982253B (en) 1999-09-17

Family

ID=21913362

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9802253A ZA982253B (en) 1997-03-17 1998-03-17 Therapeutic compositions.

Country Status (11)

Country Link
EP (2) EP2283834B1 (fr)
JP (3) JP4740426B2 (fr)
KR (1) KR100839689B1 (fr)
CN (2) CN1315473C (fr)
AU (2) AU749638B2 (fr)
CA (1) CA2283642C (fr)
DK (2) DK1017379T3 (fr)
ES (1) ES2530753T3 (fr)
RU (1) RU2224510C2 (fr)
WO (2) WO1998041201A1 (fr)
ZA (1) ZA982253B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
EP1098655B1 (fr) 1998-07-22 2004-11-24 Metabolix, Inc. Utilisations nutritionnelles et therapeutiques d'oligomeres de 3-hydroxyalcanoate
DK1123094T3 (da) * 1998-09-15 2007-08-20 Btg Int Ltd Terapeutiske præparater (II)
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ATE425750T1 (de) * 2000-05-01 2009-04-15 Accera Inc Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
AU2001291173A1 (en) * 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1648952B1 (fr) * 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Supplements alimentaires et compositions therapeutiques comportant des derives (r)-3-hydroxybutyrates
WO2005021013A1 (fr) 2003-09-01 2005-03-10 Earthus, Inc. Polymere d'acides gras a chaine $g(b)-hydroxy courte a moyenne
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
WO2006020179A2 (fr) 2004-07-20 2006-02-23 Ketocytonyx Inc. Composes cetoniques oligomeres
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
EP2468273A3 (fr) 2005-06-20 2012-07-11 Accera, Inc. Procédé pour réduire les dommages oxydatifs et améliorer l'efficacité mitochondriale
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
ES2453941T5 (es) 2005-11-30 2017-05-31 Abbvie Inc. Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos
JP5537809B2 (ja) * 2005-12-15 2014-07-02 ネステク ソシエテ アノニム 脳機能を維持するための組成物及び方法
JP2009532496A (ja) 2006-04-03 2009-09-10 アクセラ・インコーポレーテッド 加齢に伴う記憶障害を治療するためのケト原性化合物の使用
JP5030553B2 (ja) * 2006-11-24 2012-09-19 有限会社ノーベル医学研究所 ドライマウスおよび／または唾液分泌障害を処置するための医薬
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (fr) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
CN101678043A (zh) * 2007-03-30 2010-03-24 有限会社爱泽世 生酮作用促进剂组合物
RU2459624C2 (ru) 2007-04-12 2012-08-27 Риджентс Оф Дзе Юниверсити Оф Миннесота Защитные композиции от ишемии/реперфузии и способы применения
US9175345B2 (en) 2007-07-31 2015-11-03 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
CN101969769A (zh) * 2008-01-04 2011-02-09 伊希斯创新有限公司 用作降低血脂药剂的酮体和酮体酯
WO2009116546A1 (fr) * 2008-03-18 2009-09-24 国立大学法人 岡山大学 Médiateur chimique excitateur et procédé de criblage associé
CN102105071A (zh) 2008-07-03 2011-06-22 艾克塞拉公司 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
CA2750510A1 (fr) 2009-01-24 2010-07-29 Phytopharm Plc Traitement de troubles medies par un facteur neurotrophique
DK2421808T3 (da) 2009-04-23 2013-11-04 Concert Pharmaceuticals Inc 4-Hydroxysmørsyreanaloger
US20110118528A1 (en) * 2009-10-22 2011-05-19 University Of Southern California Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
CA2805693A1 (fr) 2010-07-20 2012-01-26 Phytopharm Plc Traitement de troubles induits par la l-dopa, un agoniste de dopamine et/ou un activateur de dopamine
WO2012024187A1 (fr) 2010-08-14 2012-02-23 Abbott Laboratories Protéines de liaison bêta-amyloïdes
BR112013020620A2 (pt) * 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
WO2013007003A1 (fr) * 2011-07-08 2013-01-17 中国医学科学院基础医学研究所 Nouvelle utilisation d'acide acétylacétique pour réguler la prolifération des cellules des muscles squelettiques
EP2914251B1 (fr) 2012-11-05 2019-08-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Corps cétoniques destinés à protéger les tissus des lésions par rayonnement ionisant
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
CN105246870A (zh) 2013-03-14 2016-01-13 伊希斯创新有限公司 (r)-3-羟基丁酸(r)-3-羟基丁酯的制备方法
RU2659386C2 (ru) * 2013-03-19 2018-06-29 Юниверсити Оф Соус Флорида Композиции и способы, используемые для повышения и поддержания кетоза
DE102013012494A1 (de) * 2013-07-26 2015-01-29 Irma Baumeister Verwendung von ß-Hydroxybuttersäure und Acetessigsäure sowie ihrer Salze (ß-Hydroxybutyrat und Acetacetat) als Mittel zur Behandlung bei erworbener Hypoglycorrhachie in Folge von Meningitis, Encephalitis oder Blutung in die Liquorräume
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2016012657A1 (fr) * 2014-07-21 2016-01-28 Oulun Yliopisto Formes oligomériques du 3-hydroxybutyrate
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en) * 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
JP6710098B2 (ja) * 2016-05-10 2020-06-17 大阪瓦斯株式会社 栄養剤組成物及び栄養補助食品
WO2017213999A1 (fr) * 2016-06-07 2017-12-14 The J. David Gladstone Institutes Esters d'acides gras à chaîne moyenne de beta-hydroxybutyrate et de butanediol, compositions et procédés d'utilisation de ceux-ci
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
DK3558280T3 (da) 2016-12-21 2023-08-21 Univ Kinderspital Beider Basel Forebyggelse og behandling af migræne
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
WO2018187852A1 (fr) * 2017-04-12 2018-10-18 Cavaleri Franco Compositions de butyrate et bêta-hydroxybutyrate et leurs procédés d'utilisation
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
JP7442095B2 (ja) 2017-07-21 2024-03-04 バック・インスティテュート・フォー・リサーチ・オン・エイジング ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
CN111050779A (zh) * 2017-08-18 2020-04-21 佐藤拓己 血糖值尖峰抑制剂、食品及血糖值尖峰抑制剂的制造方法
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
WO2019147503A1 (fr) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthèse de 3-hydroxybutyryl 3-hydroxybutyrate et composés apparentés
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
AU2019282691A1 (en) * 2018-06-05 2020-12-24 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
IT201800007524A1 (it) * 2018-07-26 2020-01-26 Bio-On Spa Poliidrossialcanoati per l'uso nella prevenzione o nel trattamento di una condizione di sovrappeso o di obesita', ovvero di disfunzioni metaboliche correlate a tale condizione.
BR112021021557A2 (pt) * 2019-05-10 2021-12-28 Ketoswiss Ag Corpos de cetona confinados em microesferas
AU2020282242A1 (en) * 2019-05-28 2021-12-16 Mayo Foundation For Medical Education And Research Nutritional health supplements
KR20220016145A (ko) * 2019-05-30 2022-02-08 뉴로에너지 벤처스 인코포레이티드 글리세릴 트리스(베타-하이드록시부티레이트) 및 신경 일과성 허혈 발작
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
CN113993833B (zh) * 2019-06-12 2024-05-10 凯托利皮克斯治疗有限责任公司 酰基封端的3-羟基羧酸及其盐和酯的生产方法
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
CN110776425B (zh) * 2019-10-23 2021-02-26 清华大学 一种(r)-3-羟基丁酸及其低聚物的制备方法
JP7507580B2 (ja) * 2020-03-25 2024-06-28 大阪瓦斯株式会社 醸造酢代替物の製造方法、醸造酢代替物および醸造酢代替物含有食品
JP2021185799A (ja) * 2020-05-28 2021-12-13 大阪瓦斯株式会社 ３−ヒドロキシ酪酸含有油脂組成物
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN113200849A (zh) * 2021-04-27 2021-08-03 香港理工大学 合成的3-羟基丁酸酯低聚物或寡聚物的分离纯化方法及其在抗菌抗病毒制品中的应用
EP4256966A4 (fr) * 2021-06-01 2024-12-11 Osaka Gas Co., Ltd. Composition d'huile et de graisse contenant de l'acide 3-hydroxybutyrique
CN113866399A (zh) * 2021-11-03 2021-12-31 上海交通大学医学院附属仁济医院 肝脏酮体在急性胰腺炎病情监测和治疗上的应用
CN117243939A (zh) * 2023-11-14 2023-12-19 南京今冉生物新材料科技有限公司 一种酮体缓释物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1912406A1 (de) * 1969-03-12 1970-10-01 Basf Ag Verfahren zur Herstellung von Acetessigsaeureestern
CH626651A5 (fr) * 1976-08-06 1981-11-30 Agroferm Ag
JPS54138126A (en) * 1978-04-17 1979-10-26 Ajinomoto Co Inc Remedy for diabetes
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
DE2930405C2 (de) * 1979-07-26 1982-09-23 Optische Werke G. Rodenstock, 8000 München Stimulus-Leuchte für augenoptische Untersuchungsgertäte
FR2521857B1 (fr) * 1982-02-23 1985-10-31 Solvay Compositions pharmaceutiques contenant de l'acide 3-hydroxybutanoique ou un sel derive de cet acide et sels derives de l'acide 3-hydroxybutanoique et d'une base organique azotee
GB2126082A (en) * 1982-08-12 1984-03-21 Heinrich Schulze Pharmaceutical preparations having analgetic and cytostatic activity
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
EP0250559A1 (fr) * 1985-12-18 1988-01-07 VEECH, Richard L. Therapie de nutrition parenterale avec acides amines
US5126373A (en) * 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
BE1001209A3 (fr) * 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
CA1334575C (fr) * 1988-07-26 1995-02-28 Atsushi Hiraide Preparation liquide de substitution contenant de l'acide 3-hydroxybutyrique (acide beta-hydroxybutyrique) et ses sels
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
IT1240775B (it) * 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
JPH0733653A (ja) * 1993-06-25 1995-02-03 Suntory Ltd アセトアルデヒド毒性の抑制剤
WO1995009145A1 (fr) * 1993-09-30 1995-04-06 Eastman Chemical Company ESTERS DE GLYCEROL DE β-ACYLOXY BUTYRATES NUTRITIFS
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
JPH10120553A (ja) * 1996-10-23 1998-05-12 Eisai Co Ltd 抗痴呆薬含有製剤

Also Published As

Publication number Publication date
WO1998041201A1 (fr) 1998-09-24
AU6513298A (en) 1998-10-12
AU6556998A (en) 1998-10-12
CA2283642A1 (fr) 1998-09-24
CN1256629A (zh) 2000-06-14
EP1017379A4 (fr) 2007-01-24
EP1017379B1 (fr) 2014-12-10
CN1552315B (zh) 2010-11-10
JP5800453B2 (ja) 2015-10-28
DK2283834T3 (en) 2016-08-15
KR100839689B1 (ko) 2008-06-18
EP2283834A2 (fr) 2011-02-16
DK1017379T3 (en) 2015-02-16
JP2009173677A (ja) 2009-08-06
KR20000076379A (ko) 2000-12-26
WO1998041200A1 (fr) 1998-09-24
EP1017379A1 (fr) 2000-07-12
EP2283834A3 (fr) 2012-02-01
EP2283834B1 (fr) 2016-07-13
JP2001515510A (ja) 2001-09-18
CN1552315A (zh) 2004-12-08
JP2015042644A (ja) 2015-03-05
JP4740426B2 (ja) 2011-08-03
AU749638B2 (en) 2002-06-27
CA2283642C (fr) 2012-05-15
RU2224510C2 (ru) 2004-02-27
CN1315473C (zh) 2007-05-16
ES2530753T3 (es) 2015-03-05

Similar Documents

Publication Publication Date Title
ZA982253B (en) Therapeutic compositions.
ZA984849B (en) Compositions.
ZA987844B (en) Therapeutic combinations.
ZA987839B (en) Combination therapy.
HK1027957A1 (en) Pharmaceutical composition.
ZA9711029B (en) Therapeutic agents.
ZA974735B (en) Pharmaceutical compositions.
HK1038884A1 (en) Medicinal compositions.
ZA987843B (en) Combination therapy.
GB9702238D0 (en) Compositions
ZA977104B (en) Pharmaceutical compositions.
ZA989680B (en) Pharmaceutical composition.
IL130856A0 (en) Peroxetine compositions
ZA987797B (en) Oral compositions.
HK1022853A1 (en) Pharmaceutical compositions.
ZA9811502B (en) Novel composition.
ZA987392B (en) Pharmaceutical composition.
ZA972602B (en) Pharmaceutical compositions.
ZA982395B (en) Therapeutic composition
ZA984696B (en) Vaccine compositions V.
ZA981739B (en) Composition.
GB9705340D0 (en) Compositions
GB9703109D0 (en) Compositions
GB9712981D0 (en) Compositions
ZA982367B (en) Pharmaceutical compositions.